Foundayo is approved to treat obesity. Ozempic is not. Ozempic is approved for type 2 diabetes, and every person taking it to lose weight is taking it off-label. That difference shapes everything else in this comparison — what the trials measured, what a prescriber can write, what insurance will pay, and what dose you can even reach.
Side by side
| Foundayo | Ozempic | |
|---|---|---|
| Molecule | Orforglipron | Semaglutide |
| Approved for | Weight reduction | Type 2 diabetes |
| Weight loss use | On-label | Off-label |
| Form | Daily tablet | Weekly injection, or daily tablet |
| Maximum dose | 17.2 mg daily | 2 mg weekly |
| Weight-loss evidence | 11.1% at 72 weeks, on-label | No weight indication; the molecule reaches 14.9% at the higher Wegovy dose |
| Self-pay from | $149 | $199, then $349 |
| Weight-approved sibling | — | Wegovy |
The comparison you probably want is Foundayo vs Wegovy
Ozempic and Wegovy are the same molecule. What differs is the licence and the ceiling: Ozempic tops out at 2 mg weekly for diabetes, Wegovy goes to 2.4 mg for weight, and it is Wegovy that has the trials measuring weight as the primary endpoint.
So when someone asks whether Foundayo beats Ozempic on weight loss, the honest answer has a caveat built in. There is no on-label weight figure for Ozempic to compare against. The 14.9% everyone quotes for semaglutide comes from STEP-1, which used the Wegovy dose. Ozempic at 2 mg produces less than that, and the label does not publish a weight-loss endpoint at all.
If your goal is weight, the like-for-like comparison is Foundayo vs Wegovy — both approved for it, both with weight as the measured endpoint.
When the Ozempic comparison is the right one
Two situations make it the real question rather than a substitution for another.
You have type 2 diabetes. Then Ozempic is on-label for you and Foundayo is not: Foundayo's approval is for weight reduction, and although its programme included a trial in people with type 2 diabetes, the licensed indication is weight. Ozempic also has a cardiovascular indication in type 2 diabetes with established heart disease, which Foundayo has nothing comparable to.
Coverage. Insurers pay for diabetes drugs far more readily than for weight-loss drugs. Someone with a diabetes diagnosis may find Ozempic covered at a copay while Foundayo is refused outright, and that gap can be larger than any difference between the drugs.
Weight loss, as far as the two labels allow
Foundayo: 11.1% mean weight loss at 17.2 mg over 72 weeks in adults with obesity and without diabetes, against 2.1% on placebo. In the trial of adults with type 2 diabetes it was 9.6%. Both are primary endpoints in the approved label.
Ozempic: no weight-loss indication and no weight endpoint in the label. Weight reduction is documented in the diabetes trials as a secondary observation, and at 2 mg it is smaller than what Wegovy achieves at 2.4 mg.
The comparison people actually make — 11.1% against 14.9% — is Foundayo against Wegovy wearing the wrong name. The full breakdown by drug is in the GLP-1 weight loss results index.
Both of them now come as tablets, and neither works like the other
Ozempic is also sold as a daily tablet, which replaced Rybelsus. So this is another comparison where "the pill" is ambiguous.
- Foundayo is a small molecule. Any time of day, with or without food, no water limit, no waiting.
- Ozempic tablets are oral semaglutide — a peptide with an absorption enhancer, which needs an empty stomach, a small sip of water and a thirty-minute wait before anything else.
Both are once daily and swallowed. Only one of them fits around breakfast.
Cost
| Foundayo | Ozempic | |
|---|---|---|
| Starting dose | $149 | $199 (first two fills) |
| Middle doses | $299 | $349 |
| Top dose | $349, or $299 with the card | $499 at 2 mg |
| Tablet | — | From $149 |
| With insurance coverage | Weight drug — often excluded | Diabetes drug — usually covered |
Foundayo is cheaper at every self-pay step. The last row can reverse the whole thing: a covered Ozempic prescription at a $25 copay beats any cash price on this page, and diabetes indications get covered where weight indications get denied.
Which one
- Weight loss and no diabetes: Foundayo is approved for it and Ozempic is not — but compare against Wegovy, not Ozempic, before deciding.
- Type 2 diabetes: Ozempic is on-label, has a cardiovascular indication, and is far more likely to be covered.
- Will not inject: Foundayo, or Ozempic tablets if you can hold a daily fasting window.
- Paying cash: Foundayo, from $149.
- Insured with a diabetes diagnosis: Ozempic, almost certainly, on price alone.
Prescribing decisions belong to a clinician who knows your diagnosis, your medication list and your plan. The approvals above are what determine what they can write.
The comparisons that are like for like
Both of these put Foundayo against a drug approved for weight, which Ozempic is not: Foundayo vs Wegovy and Foundayo vs Zepbound.
Scientific References
3 sources- 1
Eli Lilly and Company
FOUNDAYO (orforglipron) tablets — Prescribing Information, §1 Indications, §2.1, §14 Table 6
DailyMed, U.S. National Library of Medicine · 2026
NIH - 2
Novo Nordisk
Ozempic self-pay pricing and dosing, NovoCare Pharmacy — verified August 2026
Manufacturer pricing programme · 2026
- 3
Wilding JPH, Batterham RL, Calanna S, et al.
Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP-1)
New England Journal of Medicine · 384(11) · 2021PMID: 33567185
NEJM
References open in a new tab. Content is reviewed against peer-reviewed literature as part of our editorial policy.
About the author
Editor, Modern Weight Science
Claudiu Gheorghe is the editor of Modern Weight Science. He is not a physician. His role is to synthesize peer-reviewed studies, clinical-trial data, and FDA prescribing information into clear, plain-language explanations, and to make sure every factual claim on the site traces back to a cited source. Any decision about starting, changing, or stopping a medication belongs with a licensed clinician who knows your history.
Every claim is checked against peer-reviewed research through our review process and fact-checking policy.
Frequently Asked Questions
Is Foundayo better than Ozempic for weight loss?
Foundayo is approved for weight loss and Ozempic is not, which is the more important difference. Ozempic is licensed for type 2 diabetes and using it for weight is off-label. Its label publishes no weight-loss endpoint, and the 14.9% figure usually attributed to it belongs to Wegovy — the same molecule at 2.4 mg rather than Ozempic's 2 mg ceiling. If weight is the goal, compare Foundayo with Wegovy.
Can I get Ozempic for weight loss instead of Foundayo?
It is prescribed off-label for weight, and people do get it that way, usually because of cost or coverage. But it is capped at 2 mg where the weight-approved version reaches 2.4 mg, so it delivers less than the figures commonly quoted, and insurers increasingly check the diagnosis. If you have type 2 diabetes, Ozempic is on-label for you and likely to be covered; if you do not, Foundayo or Wegovy are the drugs designed for the job.
Which is cheaper, Foundayo or Ozempic?
Foundayo, at every self-pay step: $149 at the starting dose against $199, $299 in the middle doses against $349, and $299 at the top dose with the savings card against $499 for Ozempic 2 mg. That reverses completely with insurance. Diabetes drugs are covered far more readily than weight-loss drugs, so a covered Ozempic prescription at a $25 copay beats any cash price here.
Are Foundayo and Ozempic both pills?
Both are available as daily tablets, but they behave differently. Foundayo is a small molecule taken any time with or without food. Ozempic tablets are oral semaglutide, a peptide with an absorption enhancer, which requires an empty stomach, no more than a small sip of water, and a thirty-minute wait before eating or taking anything else. Ozempic is also available as the weekly injection most people know it as.
Does Foundayo have a cardiovascular indication like Ozempic?
No. Ozempic carries an indication for reducing major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease. Foundayo has no comparable approval and no published cardiovascular outcomes trial. For someone with both diabetes and heart disease, that is a substantial point in Ozempic's favour.
Continue learning
Where to read next
Not medical advice. This guide is for general education only. GLP-1 medications, dosing, and treatment suitability are decisions for you and a licensed clinician who knows your full medical history.